Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018

Feb. 15, 2012 - PRLog -- GlobalData has estimated the global unstable angina therapeutics market to be worth $2,834.0m in 2010. It is expected to grow to $3,139.1m with a Compound Annual Growth Rate (CAGR) of 1.3% by 2018. This slow growth can be primarily attributed to the rise in the number of patients undergoing treatment for unstable angina and the expected approval of novel therapies such as rivaroxaban, varespladib and otamixaban, which are currently in the late stage of clinical development. However, if approved, these products are expected to be marketed at a premium price compared to other treatment options for unstable angina. The launch of products at premium prices is attributed to the novel mechanism of action of these products leading to a marked improvement in efficacy and safety over the currently marketed products. Therefore the market penetration of these products is expected to remain low in a generics dominated market, limiting the growth rate of the unstable angina therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in European countries, and Crestor (rosuvastatin) in 2016. The patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the unstable angina therapeutics market is expected to witness slow growth with numerous generics playing a major role in the forecast period; this is similar to the present market scenario

GlobalData assessed the current competitive landscape for unstable angina drugs and found that competition is weak. The available treatment options are moderately successful in meeting the market demand. The market has various treatment options available but none are able to adequately manage unstable angina. The products currently available in the market are associated with average efficacy and safety profiles

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...


The current treatment options offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. As the products currently in the market do not serve the unmet need, the market continues to present opportunities for pipeline products with novel mechanisms of action and disease modifying characteristics. The unmet need in the unstable angina market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.



GlobalData, the industry analysis specialist, has released its new report, “Unstable Angina Therapeutics
- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global unstable angina therapeutics market. The report identifies the key trends shaping and driving the global unstable angina therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global unstable angina therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Unstable...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.